SG Americas Securities LLC Purchases 42,352 Shares of Zimmer Biomet Holdings, Inc. $ZBH

SG Americas Securities LLC grew its position in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 69.3% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 103,462 shares of the medical equipment provider’s stock after purchasing an additional 42,352 shares during the period. SG Americas Securities LLC owned about 0.05% of Zimmer Biomet worth $9,303,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Legacy Wealth Asset Management LLC raised its holdings in shares of Zimmer Biomet by 2.3% during the 3rd quarter. Legacy Wealth Asset Management LLC now owns 4,670 shares of the medical equipment provider’s stock valued at $460,000 after buying an additional 106 shares in the last quarter. Global Retirement Partners LLC lifted its position in Zimmer Biomet by 7.0% in the 3rd quarter. Global Retirement Partners LLC now owns 1,686 shares of the medical equipment provider’s stock worth $166,000 after buying an additional 111 shares during the last quarter. Cullen Frost Bankers Inc. lifted its position in Zimmer Biomet by 66.7% in the 3rd quarter. Cullen Frost Bankers Inc. now owns 290 shares of the medical equipment provider’s stock worth $29,000 after buying an additional 116 shares during the last quarter. Generali Asset Management SPA SGR boosted its stake in Zimmer Biomet by 0.9% in the third quarter. Generali Asset Management SPA SGR now owns 14,232 shares of the medical equipment provider’s stock worth $1,402,000 after buying an additional 122 shares in the last quarter. Finally, Brookstone Capital Management boosted its stake in Zimmer Biomet by 1.3% in the third quarter. Brookstone Capital Management now owns 9,350 shares of the medical equipment provider’s stock worth $921,000 after buying an additional 123 shares in the last quarter. 88.89% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity

In other news, SVP Lori Winkler sold 2,650 shares of the company’s stock in a transaction dated Thursday, March 12th. The shares were sold at an average price of $94.66, for a total transaction of $250,849.00. Following the completion of the transaction, the senior vice president directly owned 10,224 shares of the company’s stock, valued at approximately $967,803.84. This represents a 20.58% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Insiders own 0.70% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts have commented on the stock. Wall Street Zen downgraded shares of Zimmer Biomet from a “buy” rating to a “hold” rating in a research note on Saturday, February 14th. Wells Fargo & Company increased their target price on shares of Zimmer Biomet from $93.00 to $98.00 and gave the company an “equal weight” rating in a report on Wednesday, February 11th. UBS Group reiterated a “sell” rating and issued a $89.00 target price on shares of Zimmer Biomet in a research report on Wednesday, February 11th. TD Cowen raised shares of Zimmer Biomet from a “hold” rating to a “buy” rating in a research note on Monday, January 26th. Finally, The Goldman Sachs Group lowered shares of Zimmer Biomet from a “neutral” rating to a “sell” rating and set a $93.00 price target for the company. in a research report on Friday, January 9th. One equities research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, ten have given a Hold rating and four have issued a Sell rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $106.20.

Zimmer Biomet Stock Performance

Shares of ZBH stock opened at $88.41 on Monday. The company has a market capitalization of $17.30 billion, a P/E ratio of 24.98, a PEG ratio of 1.81 and a beta of 0.58. Zimmer Biomet Holdings, Inc. has a fifty-two week low of $84.59 and a fifty-two week high of $114.44. The company has a debt-to-equity ratio of 0.55, a quick ratio of 1.10 and a current ratio of 1.98. The stock has a 50 day moving average price of $92.00 and a two-hundred day moving average price of $94.01.

Zimmer Biomet (NYSE:ZBH) last issued its earnings results on Tuesday, February 10th. The medical equipment provider reported $2.42 EPS for the quarter, topping the consensus estimate of $2.38 by $0.04. Zimmer Biomet had a net margin of 8.56% and a return on equity of 12.93%. The company had revenue of $2.24 billion for the quarter, compared to the consensus estimate of $2.22 billion. During the same period in the previous year, the firm earned $2.31 earnings per share. The firm’s revenue for the quarter was up 10.9% on a year-over-year basis. Zimmer Biomet has set its FY 2026 guidance at 8.300-8.450 EPS. Analysts expect that Zimmer Biomet Holdings, Inc. will post 8.22 earnings per share for the current year.

Zimmer Biomet Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, April 30th. Shareholders of record on Tuesday, March 31st will be given a $0.24 dividend. The ex-dividend date is Tuesday, March 31st. This represents a $0.96 dividend on an annualized basis and a dividend yield of 1.1%. Zimmer Biomet’s payout ratio is presently 27.12%.

About Zimmer Biomet

Zimmer Biomet (NYSE: ZBH) is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company’s product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.